Cello Health BioConsulting
  • menu
  • Home
  • About us
    • Why We’re Different
    • Our Team
    • Mission, Vision & Values
  • Capabilities
    • Common Client Dilemmas
    • Opportunity Assessments
    • Opportunity Search and Evaluation
    • Portfolio and Platform Strategy
    • Business Development & Partnering Strategy
    • Market Access Strategy
    • Early Stage Strategy
  • Our Insights
    • News
    • Presentations
    • Testimonials
    • Events
  • Careers
    • Current Opportunities
    • A Day in the Life
    • Our Culture
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

View Article +
KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

View Article +
Celgene pays Immatics $75M to work on solid tumor cell therapies

Celgene pays Immatics $75M to work on solid tumor cell therapies

View Article +
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

View Article +
Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

View Article +
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

View Article +
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

View Article +
Delivering CNS-focused patient innovations

Delivering CNS-focused patient innovations

View Article +
NANOBIOTIX announces first ever radioenhancer to receive European market approval

NANOBIOTIX announces first ever radioenhancer to receive European market approval

View Article +
Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

View Article +
  2. ←
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. 9
  12. →

Search

Elsewhere

Let’s work together

Contact us

  • Cello Health BioConsulting
  • 25-B Hanover Road
  • Suite 320
  • Florham Park, NJ
  • 07932
  • USA
  • +1 973 292 5001
  •  
  • Part of Cello Health plc

    Follow us

    Cello Health BioConsulting

    ©2021 Defined Health, now known as Cello Health BioConsulting | Privacy policy.

    View Presentation

    View Presentation

    Please fill the form to access the presentation.
    • This field is for validation purposes and should be left unchanged.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Defined Health, now known as Cello Health BioConsulting
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!